Effective August 1, 2026, CPT code 81345 (TERT gene analysis for thyroid carcinoma and glioblastoma multiforme) now requires precertification/prior authorization through Carelon Medical Benefits Management for New York Medicaid beneficiaries. Ordering and servicing providers must submit authorization requests via the Carelon provider portal, Availity Essentials, or email before performing this genetic test.
Get alerts when payers change rules like this one
We check Anthem BCBS and other payers every day and email you when a change matches your specialty and state.
01Billing team and ordering providers must implement prior authorization requirement for CPT 81345 in all systems and workflows.
02Update billing software to flag CPT 81345 as requiring Carelon Medical Benefits Management precertification before claim submission.
03Providers must obtain prior authorization through one of three methods: (1) Carelon provider portal at https://providerportal.com (24/7 access, recommended), (2) Availity Essentials at https://Availity.com, or (3) email to MedicalBenefitsManagement.guidelines@Carelon.com.
04Add CPT 81345 to encounter forms and pre-visit planning tools with a reminder to obtain authorization.
05Update front desk and clinical staff that this genetic test requires precertification.
If missed: Failure to obtain prior authorization will result in claim denials for New York Medicaid members effective August 1, 2026.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.